

BUYTP: Rs 700 | ▲ 20%

INDUSIND BANK

Banking

31 October 2020

Credit buffer buildup nearly complete; growth in focus next

IndusInd Bank's (IIB) Q2FY21 PAT at Rs 6.6bn (-53% YoY) saw the impact of elevated provisions, as expected. PCR has risen to ~77% and initiatives to strengthen the balance sheet will be completed over the next couple of quarters. Slippages (ex-SC stay) declined to Rs 6bn with negligible fresh corporate NPAs. IIB expects the overall restructuring pool to be in low single digits. Collection efficiency has risen to ~96%, and management expects a growth pickup in H2. We raise FY22-FY23 EPS 5-8% and revise our Sep'21 TP to Rs 700 (vs. Rs 620).

Vikesh Mehta research@bobcaps.in

Provisioning buffer strengthens further: Fresh slippages reduced to ~Rs 4bn, leading to a lower GNPA ratio of 2.2% (2.3% ex-SC stay on loan classification, vs. 2.5% in Q1). IIB's overall collection efficiency stood at 94.7% in Sep'20 and has further improved to 95.5-96% currently (94% and 93% respectively in vehicle financing and MFI). Management expects the FY21 restructuring book to be in low single digits. PCR rose to 76.5% in Q2 while Covid-related provisions increased to 1.1% of loans. IIB aims to continue fortifying its credit buffers over the next couple of quarters and to renew its earnings growth focus in FY22.

Growth likely to pick up in H2FY21; NIM to normalise: Loan growth remained muted at 2% YoY in Q2 as the corporate book declined 5% given that loans worth Rs 19bn were repaid. Management expects a better H2FY21 with vehicle finance, microfinance, secured retail and mid-corporates being the key growth drivers. Surplus liquidity had a 10bps impact on NIM which declined QoQ to 4.2% in Q2 but should normalise as demand revives.

Maintain BUY: We believe building high credit reserves is a step in the right direction. Profitability will be subdued in FY21-FY22 but we expect recovery by FY23. We raise FY22-FY23 EPS by 5-8% to factor in higher credit growth and now value IIB at 1.1x P/BV (1x earlier) for a revised Sep'21 TP of Rs 700.

KEY FINANCIALS

Y/E 31 Mar	FY19A	FY20P	FY21E	FY22E	FY23E
Net interest income	88,462	120,587	131,607	148,347	173,401
NII growth (%)	18.0	36.3	9.1	12.7	16.9
Adj. net profit (Rs mn)	33,011	44,579	28,635	57,452	68,951
EPS (Rs)	54.9	68.8	39.5	76.0	91.2
P/E (x)	10.7	8.5	14.8	7.7	6.4
P/BV (x)	1.3	1.2	1.1	1.0	0.9
ROA (%)	1.3	1.5	0.9	1.7	1.8
ROE (%)	13.1	14.5	7.5	13.0	14.0

Source: Company, BOBCAPS Research

Ticker/Price	IIB IN/Rs 586
Market cap	US\$ 5.9bn
Shares o/s	756mn
3M ADV	US\$ 146.9mn
52wk high/low	Rs 1,597/Rs 236
Promoter/FPI/DII	15%/52%/33%

Source: NSE

STOCK PERFORMANCE



Source: NSE





FIG 1 – QUARTERLY PERFORMANCE

(Rs mn)	Q2FY21	Q2FY20	Q1FY21	Y ₀ Y (%)	Q ₀ Q (%)	6MFY21	6MFY20	Y ₀ Y (%)
Income Statement								
Interest income	71,772	71,504	71,617	0.4	0.2	143,389	141,117	1.6
Interest expense	38,992	42,410	38,525	(8.1)	1.2	77,518	83,584	(7.3)
Net interest income	32,780	29,094	33,092	12.7	(0.9)	65,872	57,533	14.5
Non-interest income	15,543	17,272	15,204	(10.0)	2.2	30,748	33,904	(9.3)
Net total income	48,323	46,365	48,296	4.2	0.1	96,619	91,438	5.7
Staff expenses	7,248	7,165	7,429	1.2	(2.4)	14,677	13,637	7.6
Other operating expenses	12,555	12,966	11,590	(3.2)	8.3	24,145	25,657	(5.9)
Operating expenses	19,803	20,131	19,019	(1.6)	4.1	38,822	39,294	(1.2)
Pre-provisioning profit	28,520	26,234	29,277	8.7	(2.6)	57,797	52,144	10.8
Total provisions	19,644	7,377	22,589	166.3	(13.0)	42,233	11,683	261.5
Profit before tax	8,875	18,857	6,689	(52.9)	32.7	15,564	40,461	(61.5)
Tax	2,245	4,848	1,585	(53.7)	41.6	3,830	12,126	(68.4)
Profit after tax	6,631	14,010	5,103	(52.7)	29.9	11,734	28,335	(58.6)
Balance Sheet								
Advances	2,012,468	1,971,126	1,980,690	2.1	1.6	2,012,468	1,971,126	2.1
Deposits	2,278,842	2,071,934	2,112,650	10.0	7.9	2,278,842	2,071,934	10.0
CASA ratio (%)	40.3	41.4	40.0	(113bps)	32bps	40.3	41.4	(113bps)
Yields and margins (%)								
Net interest margin	4.2	4.1	4.3	6bps	(12bps)	-	-	-
Yield on advances	12.0	12.0	11.9	(7bps)	12bps	-	-	-
Cost of funds	4.9	5.9	5.1	(96bps)	(16bps)	-	-	-
Key ratios (%)								
Cost/Income	41.0	43.4	39.4	(244bps)	160bps	40.2	43.0	(279bps)
Tax rate	25.3	25.7	23.7	(42bps)	159bps	24.6	30.0	(536bps)
Loan to Deposit ratio	88.3	95.1	93.8	(682bps)	(544bps)	88.3	95.1	(682bps)
Capital adequacy ratios (%)								
Tier 1	15.8	14.3	14.5	156bps	134bps	15.8	14.3	156bps
Total CAR	16.6	14.7	15.2	185bps	139bps	16.6	14.7	185bps
Asset quality (Rs mn)								
Gross NPAs	45,322	43,702	50,990	3.7	(11.1)	45,322	43,702	3.7
Net NPAs	10,558	22,026	17,034	(52.1)	(38.0)	10,558	22,026	(52.1)
Gross NPA ratio (%)	2.2	2.2	2.5	2bps	(32bps)	2.2	2.2	2bps
Net NPA ratio (%)	0.5	1.1	0.9	(60bps)	(34bps)	0.5	1.1	(60bps)
		48.9				76.5		

Source: Company, BOBCAPS Research



Valuation methodology

We like IIB's aggressive stance of front-loading provisions which may depress FY21-FY22 profitability but allow for a rebound by FY23 on the back of better growth and contained provisions. We raise FY22-FY23 EPS estimates by 5-8% to factor in higher credit growth and now value IIB at 1.1x P/BV (1x earlier) for a revised Sep'21 target price of Rs 700 (Rs 620 earlier). Maintain BUY.

FIG 2 - REVISED ESTIMATES

Particulars	New		Old			Change (%)			
Farticulars	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E
Net interest income (Rs mn)	131,607	148,347	173,401	131,607	145,362	164,475	=	2.1	5.4
Pre-provisioning profit	113,029	126,545	148,815	112,481	120,877	138,943	0.5	4.7	7.1
Net Profit (Rs mn)	28,635	57,452	68,951	28,239	54,496	64,067	1.4	5.4	7.6
EPS (Rs)	40	76	91	39	72	85	1.4	5.4	7.6

Source: BOBCAPS Research

FIG 3 - RELATIVE STOCK PERFORMANCE



Source: NSE

Key risks

- Higher funding costs can impact our NIM assumptions.
- An above-anticipated rise in credit cost from the corporate/retail book poses a risk to estimates.



FINANCIALS

Income Statement

Y/E 31 Mar (Rs mn)	FY19A	FY20P	FY21E	FY22E	FY23E
Net interest income	88,462	120,587	131,607	148,347	173,401
NII growth (%)	18.0	36.3	9.1	12.7	16.9
Non-interest income	56,467	69,527	64,974	71,309	81,682
Total income	144,929	190,114	196,581	219,656	255,083
Operating expenses	(64,047)	(81,826)	(83,551)	(93,111)	(106,268)
Operating profit	80,882	108,288	113,029	126,545	148,815
Operating profit growth (%)	21.5	33.9	4.4	12.0	17.6
Provisions	(31,077)	(46,521)	(73,354)	(46,941)	(53,278)
PBT	49,806	61,767	39,676	79,604	95,537
Tax	(16,795)	(17,189)	(11,041)	(22,152)	(26,586)
Reported net profit	33,011	44,579	28,635	57,452	68,951
Adjustments	0	0	0	0	0
Adjusted net profit	33,011	44,579	28,635	57,452	68,951

Balance Sheet

Y/E 31 Mar (Rs mn)	FY19A	FY20P	FY21E	FY22E	FY23E
Equity capital	6,027	6,935	7,563	7,563	7,563
Reserves & surplus	260,833	340,545	409,088	456,458	513,309
Net worth	266,860	347,480	416,651	464,021	520,871
Deposits	1,948,679	2,020,270	2,135,125	2,424,203	2,784,214
Borrowings	473,211	607,535	611,204	628,532	655,375
Other liabilities & provisions	89,444	97,000	102,508	108,333	114,494
Total liabilities and equities	2,778,194	3,072,286	3,265,487	3,625,089	4,074,954
Cash & bank balance	147,834	160,541	173,688	188,083	203,850
Investments	592,662	599,384	654,255	726,889	828,102
Advances	1,863,935	2,067,832	2,207,206	2,494,143	2,893,205
Fixed & Other assets	173,764	244,529	230,338	215,974	149,796
Total assets	2,778,194	3,072,286	3,265,487	3,625,089	4,074,954
Deposit growth (%)	28.5	3.7	5.7	13.5	14.9
Advances growth (%)	28.6	10.9	6.7	13.0	16.0

Per Share

Y/E 31 Mar (Rs)	FY19A	FY20P	FY21E	FY22E	FY23E
EPS	54.9	68.8	39.5	76.0	91.2
Dividend per share	9.0	9.0	5.7	11.4	13.7
Book value per share	437.4	496.4	546.7	609.3	684.5

Source: Company, BOBCAPS Research



Valuations Ratios

Y/E 31 Mar (x)	FY19A	FY20P	FY21E	FY22E	FY23E
P/E	10.7	8.5	14.8	7.7	6.4
P/BV	1.3	1.2	1.1	1.0	0.9
Dividend yield (%)	1.5	1.5	1.0	1.9	2.3

DuPont Analysis

Y/E 31 Mar (%)	FY19A	FY20P	FY21E	FY22E	FY23E
Net interest income	3.5	4.1	4.2	4.3	4.5
Non-interest income	2.3	2.4	2.1	2.1	2.1
Operating expenses	2.6	2.8	2.6	2.7	2.8
Pre-provisioning profit	3.2	3.7	3.6	3.7	3.9
Provisions	1.2	1.6	2.3	1.4	1.4
PBT	2.0	2.1	1.3	2.3	2.5
Tax	0.7	0.6	0.3	0.6	0.7
ROA	1.3	1.5	0.9	1.7	1.8
Leverage (x)	9.9	9.5	8.3	7.8	7.8
ROE	13.1	14.5	7.5	13.0	14.0

Ratio Analysis

,					
Y/E 31 Mar	FY19A	FY20P	FY21E	FY22E	FY23E
YoY growth (%)					
Net interest income	18.0	36.3	9.1	12.7	16.9
Pre-provisioning profit	21.5	33.9	4.4	12.0	17.6
EPS	(8.8)	25.3	(42.6)	92.3	20.0
Profitability & Return ratios (%)					
Net interest margin	3.8	4.4	4.5	4.6	4.7
Fees / Avg. assets	1.6	1.6	1.3	1.3	1.4
Cost-Income	44.2	43.0	42.5	42.4	41.7
ROE	13.1	14.5	7.5	13.0	14.0
ROA	1.3	1.5	0.9	1.7	1.8
Asset quality (%)					
GNPA	2.1	2.5	3.6	3.4	3.0
NNPA	1.2	0.9	1.0	0.9	0.8
Provision coverage	43.0	63.3	72.4	72.7	72.2
Ratios (%)					
Credit-Deposit	95.7	102.4	103.4	102.9	103.9
Investment-Deposit	30.4	29.7	30.6	30.0	29.7
CAR	14.2	15.0	17.9	17.5	17.3
Tier-1	13.7	14.6	17.3	16.8	16.5

Source: Company, BOBCAPS Research



Disclaimer

Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%


ADD - Expected return from >+5% to +15%

REDUCE - Expected return from -5% to +5%

SELL - Expected return <-5%

Note: Recommendation structure changed with effect from 1 January 2018 (Hold rating discontinued and replaced by Add / Reduce)

RATINGS AND TARGET PRICE (3-YEAR HISTORY): INDUSIND BANK (IIB IN)



B - Buy, A - Add, R - Reduce, S - Sell

Rating distribution

As of 30 September 2020, out of 104 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 54 have BUY ratings, 18 have ADD ratings, 10 are rated REDUCE and 22 are rated SELL. None of these companies have been investment banking clients in the last 12 months.

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2020. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations

INDUSIND BANK



expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities —that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company in the past 12 months. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.